Todos os estudos
Inscrição por conviteFASE2, FASE3INTERVENCIONISTA

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

This study is an extension of previous research, focusing on the long-term safety, how well it's tolerated, and the effectiveness of a medicine called tividenofusp alfa. This medicine is for children with a rare condition called Hunter syndrome, also known as Mucopolysaccharidosis Type II (MPS II). It's given through an IV (into a vein) and aims to help the brain and spinal cord. If you've already been part of related studies (DNLI-E-0002 or DNLI-E-0007) and meet certain conditions, you might be able to join this study. Participants will receive the medicine for up to 5 years, and for some, the original treatment they received in a previous study will remain unknown to everyone involved, ensuring fair evaluation.

Em resumo

Status
Inscrição por convite
Fase
FASE2, FASE3
Patrocinador
Denali Therapeutics Inc.
Meta de inscrição
99
Iniciar
20 Sep 2023
Conclusão estimada
01 Jun 2027

Sobre o que é este estudo?

This study is an important next step for children living with Hunter syndrome, also known as Mucopolysaccharidosis Type II (MPS II). MPS II is a rare genetic condition that can affect many parts of the body, including the brain and spinal cord. Currently, treatments are available, but doctors are always looking for ways to improve care and find new options.

This particular study is testing a new investigational medicine called tividenofusp alfa (also known as DNL310). It's given through a drip into a vein (IV) and is designed to reach the brain and spinal cord. The main goal is to see how safe this medicine is over a longer period and how well children tolerate it. Researchers also want to understand how effective it is in managing the symptoms of Hunter syndrome long-term.

Because this is an 'extension study,' it's specifically for children who have already taken part in similar research studies (DNLI-E-0002 or DNLI-E-0007). By continuing to monitor these participants, researchers can gather valuable information about the medicine's long-term effects, which is crucial for helping to develop new treatments.

Pontos principais

  • This study is for children with Hunter syndrome (MPS II).
  • It's testing a new medicine called tividenofusp alfa given by IV.
  • O principal objetivo é verificar sua segurança a longo prazo e quão bem ele funciona.
  • Only children who completed previous studies (DNLI-E-0002 or DNLI-E-0007) can join.
  • Participation could last up to 5 years, with regular clinic visits.
  • Você pode parar de participar a qualquer momento.

Quem pode ser elegível?

This study is for children who have already taken part in one of two previous research studies for Hunter syndrome (MPS II): Study DNLI-E-0002 or Study DNLI-E-0007.

If you were in Study DNLI-E-0002, you would need to have completed at least 49 weeks of that study and not have stopped the treatment early. If you were in Study DNLI-E-0007, you would need to have finished the entire treatment period in that study.

You would not be able to join this study if you have any serious or uncontrolled medical issues, or other health problems that the study doctors believe would make it unsafe for you to participate or would make it difficult to properly understand the study results.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Have you or your child been diagnosed with Hunter syndrome (MPS II)?
  2. Did you or your child participate in study DNLI-E-0002 and complete at least 49 weeks without stopping early?
  3. OR, did you or your child participate in study DNLI-E-0007 and complete the entire treatment period?
  4. Do you or your child have any uncontrolled medical conditions or other health issues that a doctor might consider too significant for study participation?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you will receive the study medicine, tividenofusp alfa, for up to 5 years. The medicine is given through an IV (intravenously), meaning it will be delivered directly into your bloodstream, likely at a hospital or clinic. Throughout this period, you will have regular visits to the study site. During these visits, the study team will carefully check your health, how you are feeling, and any effects the medicine might be having. They will perform various assessments to monitor the safety of the treatment and see how well it's working. These assessments might include physical exams, blood tests, and other procedures relevant to Hunter syndrome. The exact schedule of visits and tests will be explained in detail by the study team.

Riscos e benefícios potenciais

Taking part in any study has potential benefits and risks. The main potential benefit of this study is continued access to the investigational medicine tividenofusp alfa, which aims to help with Hunter syndrome. It contributes to understanding long-term safety and effectiveness, possibly leading to a new approved treatment. Potential risks could include side effects from the medicine, discomfort from IV infusions, or the time commitment for study visits. It's important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Locations (31)

  • UCSF Benioff Children's Hospital Oakland
    Código postal verificado
    Oakland, Estados Unidos
  • Ann and Robert H Lurie Children's Hospital of Chicago
    Código postal verificado
    Chicago, Estados Unidos
  • Hackensack University Medical Center
    Código postal verificado
    Hackensack, Estados Unidos
  • UNC Children's Research Institute
    Código postal verificado
    Chapel Hill, United States
  • Cincinnati Children's Hospital Medical Center
    Código postal verificado
    Cincinnati, Estados Unidos
  • Hospital Infantil da Filadélfia
    Código postal verificado
    Filadélfia, Estados Unidos
  • The University of Texas Medical School at Houston
    Código postal verificado
    Houston, Estados Unidos
  • Huntsman Cancer Hospital
    Código postal verificado
    Salt Lake City, United States
  • Sanatorio Mater Dei
    Código postal verificado
    Buenos Aires, Argentina
  • Universitair Ziekenhuis Antwerpen
    Código postal verificado
    Edegem, Belgium
  • UZ Brussel
    Código postal verificado
    Jette, Belgium
  • Hospital Clinicas Porto Alegre
    Código postal verificado
    Porto Alegre, Brazil

Perguntas frequentes

What is Hunter syndrome (MPS II)?

Hunter syndrome is a rare genetic condition where the body can't break down certain complex sugars, leading to their build-up and causing various health problems, including developmental challenges.

What is tividenofusp alfa?

Tividenofusp alfa is an investigational medicine being tested in this study. It's designed to help the body process the substances that build up in Hunter syndrome, especially in the brain and spinal cord.

Como o medicamento é administrado?

The medicine is given through a drip into a vein, which is called an intravenous (IV) infusion.

How long will I be in this study?

If you join, you could receive the study medicine and be monitored for up to 5 years.

Can I join if I haven't been in a previous study?

No, this study is an extension and is only for children who have already participated in specific earlier studies (DNLI-E-0002 or DNLI-E-0007).

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "An Extension Study of the Long-Term Safety, Tolerability, an…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.